The Food and Drug Administration (FDA) approved Symlin, an injectable medicine to control blood sugar for adults with type 1 and type 2 diabetes. Symlin is to be used in addition to insulin therapy in patients who cannot achieve adequate control of their blood sugars on intensive insulin therapy alone.
The Food and Drug Administration (FDA) has granted approval of a new indication for Temodar (temozolomide). The drug, used concurrently with radiotherapy and as maintenance therapy after radiotherapy, can extend the lives of adult patients newly diagnosed with glioblastoma multiforme (GBM), the most common form of malignant brain cancer.
Acupuncture and exercise can help relieve pelvic pain during pregnancy, Swedish researchers said.
Adding etidronate to calcium and vitamin D therapy is not necessary in the treatment of bone loss in patients with Crohn’s disease, results of a new study indicate. “The addition of the bone-building drug etidronate adds no additional advantage,” Dr. Richard N. Fedorak told.
The Food and Drug Administration (FDA) issued a public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (nataluzimab) while the agency and the manufacturer evaluate two serious adverse events reported with its use.
Heart disease affects women of all racial and ethnic groups, as well as women with other illnesses, such as diabetes.
For people with low levels of “good” (HDL) cholesterol and coronary disease, treatment aimed at increasing HDL levels is worthwhile, researchers report.
The Food and Drug Administration (FDA) approved a new intravenous biologic product, palifermin (trade-name Kepivance) to help reduce the chance that certain cancer patients, those with blood cancers undergoing chemotherapy and radiation in preparation for bone marrow transplants, will develop mucositis. Palifermin also shortens the duration of the condition.
A new test can predict both the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy, according to research supported by the National Cancer Institute (NCI), part of the National Institutes of Health, and performed in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health Inc. These results suggest that almost half of 43,000 U.S. women diagnosed with estrogen-dependent, lymph-node negative breast cancer every year are at low risk for recurrence and may not need to go through the discomfort and side effects of chemotherapy.
Cold weather enthusiasts may eagerly await the snowy days of winter, but for those with seasonal affective disorder, the change from sunny to gloomy days often brings on a similar change in mood.